80 related articles for article (PubMed ID: 22650230)
1. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.
Kim E; Matsuse M; Saenko V; Suzuki K; Ohtsuru A; Mitsutake N; Yamashita S
Thyroid; 2012 Jul; 22(7):717-24. PubMed ID: 22650230
[TBL] [Abstract][Full Text] [Related]
2. Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer.
Pozdeyev N; Berlinberg A; Zhou Q; Wuensch K; Shibata H; Wood WM; Haugen BR
PLoS One; 2015; 10(8):e0134901. PubMed ID: 26263379
[TBL] [Abstract][Full Text] [Related]
3. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
[TBL] [Abstract][Full Text] [Related]
4. Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.
Venalis P; Maurer B; Akhmetshina A; Busch N; Dees C; Stürzl M; Zwerina J; Jüngel A; Gay S; Schett G; Distler O; Distler JH
J Cell Mol Med; 2009 Oct; 13(10):4185-91. PubMed ID: 18774958
[TBL] [Abstract][Full Text] [Related]
5. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
Narendrula R; Mispel-Beyer K; Guo B; Parissenti AM; Pritzker LB; Pritzker K; Masilamani T; Wang X; Lannér C
BMC Cancer; 2016 Feb; 16():146. PubMed ID: 26911141
[TBL] [Abstract][Full Text] [Related]
6. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF
Br J Cancer; 2015 Mar; 112(5):832-40. PubMed ID: 25647012
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.
Li Z; Jiang X; Chen P; Wu X; Duan A; Qin Y
Oncol Lett; 2018 Sep; 16(3):4033-4042. PubMed ID: 30128025
[TBL] [Abstract][Full Text] [Related]
8. NF-κB in biology and targeted therapy: new insights and translational implications.
Guo Q; Jin Y; Chen X; Ye X; Shen X; Lin M; Zeng C; Zhou T; Zhang J
Signal Transduct Target Ther; 2024 Mar; 9(1):53. PubMed ID: 38433280
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management.
Yuan J; Guo Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612173
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial.
Dong Z; Ni B; Yang L; Guan Y; Zhu C; Zhao E; Zhao G; Xia X; Zhang Z
Front Surg; 2022; 9():917352. PubMed ID: 35836597
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancer
Tao J; Tan Z; Diao L; Ji Z; Zhu J; Chen W; Hu Y
RSC Adv; 2018 Jun; 8(39):21735-21744. PubMed ID: 35541720
[TBL] [Abstract][Full Text] [Related]
12. Advances in targeted therapy for anaplastic thyroid carcinoma.
Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2-3-positive nasopharyngeal carcinoma patients.
Tao HY; Liu H; He F; He CX; Li R; Du KP; Yuan YW; Zheng RH
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2959-2969. PubMed ID: 34822015
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics.
Li S; Zhang F; Xiao X; Guo Y; Wen Z; Li M; Pu X
Front Pharmacol; 2021; 12():634097. PubMed ID: 33986671
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
Xiong L; Lin XM; Nie JH; Ye HS; Liu J
Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
[No Abstract] [Full Text] [Related]
16. Recent advances in the management of anaplastic thyroid cancer.
De Leo S; Trevisan M; Fugazzola L
Thyroid Res; 2020 Nov; 13(1):17. PubMed ID: 33292371
[TBL] [Abstract][Full Text] [Related]
17. Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer.
Xu J; Qiu Y
Asian J Androl; 2019; 21(3):270-278. PubMed ID: 30924449
[TBL] [Abstract][Full Text] [Related]
18. CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.
Wang T; Zhan Q; Peng X; Qiu Z; Zhao T
Oncol Lett; 2018 Jul; 16(1):1267-1274. PubMed ID: 30061946
[TBL] [Abstract][Full Text] [Related]
19. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
